Uterine smooth muscle tumours and the role of Ki67 expression in determining their biological behaviour

Krishna Priya K. R.; Prema Saldanha; M. H. Shariff

doi:10.18203/2320-6012.ijrms20253970

Authors

Krishna Priya K. R. Department of Pathology, Yenepoya Medical College, Mangalore, Karnataka, India
Prema Saldanha Department of Pathology, Yenepoya Medical College, Mangalore, Karnataka, India
M. H. Shariff Department of Pathology, Yenepoya Medical College, Mangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20253970

Keywords:

Uterus, Leiomyoma, Variants, STUMP, Leiomyosarcoma, Ki67

Abstract

Background: Uterine smooth muscle tumours include leiomyoma, intravenous leiomyoma, metastasizing leiomyoma, smooth muscle tumour of uncertain malignant potential (STUMP) and leiomyosarcoma (LMS). Diagnosis primarily relies on histopathological features. In cases with overlapping morphological findings, immunohistochemical markers can help in differentiating benign and malignant lesions. This study evaluates the role of Ki67 immunohistochemical expression in determining the biological behaviour of uterine smooth muscle tumours.

Methods: In this study a total of 58 cases of uterine smooth muscle tumours were analysed. Gross findings were observed. The microscopic evaluation was done on formalin fixed paraffin embedded sections and haematoxylin and eosin-stained slides. This was followed by Ki67 staining by immunohistochemistry and was graded depending on percentage of nuclear expression. Association of Ki67 grade with gross and microscopic findings were determined.

Results: Among 58 tumours, 52 (90%) were leiomyomas, 3 (5%) STUMPs, and 3 (5%) LMS. Most patients were between 41 and 50 years of age, with menorrhagia being the most common presenting complaint. Ki67 expression was low (86.2%) in all leiomyomas, consistently high in LMS and showed variable levels in STUMP. Ki67 levels demonstrated a significant association with mitotic activity, necrosis and cytologic atypia (p<0.05), but did not correlate with tumour size and secondary changes.

Conclusions: Combining histopathology with Ki67 immunostaining improves diagnostic efficacy in uterine smooth muscle tumours and thus contributes to a more effective clinical management.

Metrics

Metrics Loading ...

References

Cree IA. WHO Classification of Tumours Editorial Board, International Agency for Research on Cancer. WHO classification of female genital tumours. 5th edition. Lyon, International Agency for Research on Cancer. 2020.

Eulálio Filho WMN, Soares EAS, Lima MSO, Brazil EDDN, Rodrigues, Zeron, et al. Evaluation of KI-67 expression in uterine leiomyoma and in healthy myometrium: a pilot study. Rev Assoc Med Bras (1992). 2019 ;65(12):1459-63. DOI: https://doi.org/10.1590/1806-9282.65.12.1459

Styer AK, Rueda BR. The Epidemiology and Genetics of Uterine Leiomyoma. Best Pract Res Clin Obstet Gynaecol. 2016;34:3-12. DOI: https://doi.org/10.1016/j.bpobgyn.2015.11.018

Mathew RP, Francis S, Jayaram V, Anvarsadath S. Uterine leiomyomas revisited with review of literature. Abdom Radiol. 2021;46:4908-26. DOI: https://doi.org/10.1007/s00261-021-03126-4

Gilks B. Uterus: corpus. In: Goldblum JR, Lamps LW, McKenney JK, Myers JL, Ackerman LV, editors. Rosai and Ackerman’s Surgical Pathology. 11th ed. Philadelphia (PA): Mosby/Elsevier. 2018;1623-88.

Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumours of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstetricia et Gynecologica Scandinavica. 2004;83(11):1085-8. DOI: https://doi.org/10.1080/j.0001-6349.2004.00502.x

Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor and progesterone receptor expression in uterine smooth muscle tumours. Hum Pathol. 2001;32(9):984-7.

Delgado B, Dreiher J, Braiman D, Meirovitz M, Shaco-Levy R. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases. Int J Gynecological Pathol. 2021;40(3):257-62. DOI: https://doi.org/10.1097/PGP.0000000000000688

Kale VG, Deore BS, Nathe NS, Phadol JN, Meher AP. Histomorphological spectrum of uterine leiomyoma and its secondary changes. Int J Health Sci (Qassim). 2024;8(S1):887-99. DOI: https://doi.org/10.53730/ijhs.v8nS1.14959

Kaur M, Gupta RK, Kaur SJ, Kaur P. Clinicopathological study of leiomyomas in hysterectomy specimens. Int J Reprod Contracept Obstet Gynecol. 2018;7(4):1509. DOI: https://doi.org/10.18203/2320-1770.ijrcog20181345

Dayal S, Kumar A, Verma A. Clinicopathologic correlation of leiomyoma with clinical findings and secondary changes in a rural population of North India. Am J Clin Pathol. 2014;141(2):275-9. DOI: https://doi.org/10.1309/AJCPSLMZ1TOC4JCF

Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor and progesterone receptor expression in uterine smooth muscle tumours. Hum Pathol. 2001;32(9):984-7. DOI: https://doi.org/10.1053/hupa.2001.27113

Petrović D, Babić D, Forko JI, Martinac I. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. Coll Antropol. 2010;34(1):93-7.